###begin article-title 0
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 91 99 91 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 20 25 <span type="species:ncbi:9606">human</span>
Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitro
###end article-title 0
###begin p 1
###xml 97 136 97 136 <email xmlns:xlink="http://www.w3.org/1999/xlink">christian.mielke@med.uni-duesseldorf.de</email>
To whom correspondence should be addressed. Tel: +49 211 81 19323; Fax: +49 211 81 18021; Email: christian.mielke@med.uni-duesseldorf.de
###end p 1
###begin p 2
###xml 117 125 117 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 573 581 573 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 898 906 898 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 947 954 947 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1189 1196 1189 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 357 362 <span type="species:ncbi:9606">human</span>
DNA-topoisomerase I (topo I) unwinds the DNA- double helix by cutting one strand and allowing rotation of the other. In vitro, this function does not require the N-terminal domain of the enzyme, which is believed to regulate cellular properties. To assess this role, we studied the cellular distribution and mobility of green fluorescent protein-chimera of human topo I lacking either the entire N-terminal domain or a portion of it. We find that topo I truncated up to position 210 is not stabilized by camptothecin in covalent DNA-complexes inside a living cell, whereas in vitro it retains full DNA-relaxation activity, and is targeted by camptothecin in the usual manner. This difference is not shared with a fragment lacking the N-terminal domain up to position 190, indicating that residues 190-210 play a crucial role for the activity of the enzyme in its physiological environment, but not in vitro. Since it is impossible to discriminate in vivo whether this region is required for topo I to form covalent DNA intermediates in the cell, or just for camptothecin to bind and stabilize such complexes, we could not explain precisely these cellular observations. However, inactivity in vivo of the enzyme lacking this region is indicated by a lesser cytotoxicity.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c1">1</xref>
###xml 301 302 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c2">2</xref>
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c3">3</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c4">4</xref>
###xml 400 401 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c5">5</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c6">6</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c10">10</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c11">11</xref>
DNA-topoisomerase I (topo I) changes the pitch of DNA-double helices by cutting one DNA strand and allowing rotation of the complementary strand in a controlled manner. This mechanism is well understood (1). It plays an established role in the release of torsion stress adjacent to replication forks (2) and transcription complexes (3), and may also be involved in DNA-recombination (4), DNA-damage (5), DNA-repair (6-10) and chromosome organization (11). It is unclear, how inside a living cell the enzyme is assigned to these diverse tasks and how they are orchestrated with complex nuclear processes and higher-order chromatin structure.
###end p 4
###begin p 5
###xml 36 38 36 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c12">12</xref>
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c13">13</xref>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c14">14</xref>
###xml 134 135 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 139 142 139 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">214</sup>
###xml 154 157 154 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">215</sup>
###xml 161 164 161 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">635</sup>
###xml 178 181 178 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">636</sup>
###xml 185 188 185 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">712</sup>
###xml 216 219 216 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">713</sup>
###xml 223 226 223 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">765</sup>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c13">13</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c15">15</xref>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c13">13</xref>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c14">14</xref>
###xml 632 640 632 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c16">16</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c18">18</xref>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c19">19</xref>
###xml 855 863 855 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
According to X-ray crystallography (12) and biochemical analyses (13,14) topo I is organized into four domains: N-terminal domain (Met1-Gly214), core (Ile215-Ala635), linker (Pro636-Lys712) and C-terminal domain (Gln713-Phe765). The last three domains constitute the minimal active unit of the enzyme. Together, they form a clamp-like structure carrying out the basic type I topoisomerase reactions, such as relaxation of supercoiled plasmid-DNA (13,15). The function of the N-terminal domain is less clear, because this portion has eluded structural analysis until recently (13,14). It is not essential for DNA-relaxation activity in vitro (16-18). On the other hand, evolution has preserved a similar, though mainly genetically divergent domain in all type IB topoisomerases (19), suggesting that it is essential-albeit in a manner not readily apparent in vitro or delineated by sequence motifs.
###end p 5
###begin p 6
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c9">9</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c20">20</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c23">23</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c24">24</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c25">25</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c26">26</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c27">27</xref>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c9">9</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c21">21</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c28">28</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c29">29</xref>
###xml 485 492 485 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 739 747 739 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c18">18</xref>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c17">17</xref>
###xml 1002 1005 1002 1005 <sup xmlns:xlink="http://www.w3.org/1999/xlink">201</sup>
###xml 1039 1042 1039 1042 <sup xmlns:xlink="http://www.w3.org/1999/xlink">203</sup>
###xml 1050 1053 1050 1053 <sup xmlns:xlink="http://www.w3.org/1999/xlink">346</sup>
###xml 1070 1073 1070 1073 <sup xmlns:xlink="http://www.w3.org/1999/xlink">205</sup>
###xml 1078 1081 1078 1081 <sup xmlns:xlink="http://www.w3.org/1999/xlink">206</sup>
###xml 1188 1190 1188 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c30">30</xref>
###xml 1191 1193 1191 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c31">31</xref>
###xml 1538 1546 1538 1546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1615 1617 1615 1617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c18">18</xref>
###xml 1243 1248 <span type="species:ncbi:9606">human</span>
Some functions of the N-terminal domain are known: it serves as a docking place for interacting proteins (9,20-23). It contains nuclear localization signals (NLSs) (24,25) and putative target sequences for protein phosphorylation (26,27). It influences the distribution of the enzyme in the cell and in the cell nucleus (9,21,28,29). These features suggest that the N-terminal domain provides some kind of a handle by which the catalytic machinery of topo I is controlled and directed in vivo. More recent evidence suggests that the N-terminal domain could also be involved in the catalytic process itself. It has been observed that a fragment lacking more or less the entire N-terminal domain (amino acids 1-206) has catalytic properties in vitro that are slightly different from full-length topo I (18), whereas this is not the case for a fragment lacking at the N-terminal end 16 amino acids less (17). Consistent with this, two recent X-ray crystallography studies extending the structure until Gln201 revealed interactions between Trp203 and His346, and between Trp205, Trp206 and the flexible hinge, which may be important for proper closing of the enzyme around its DNA substrate (30,31). Thus, a region within the N-terminal domain of human topo I spanning approximately residues 190-210 seems to play a role in the mechanism of DNA-catalysis, although it is not part of the genetically conserved minimal active unit of the enzyme. On the other hand, the covalent topo I-DNA cleavage complex is equally stabilized by camptothecin in vitro, irrespective of the presence or absence of the first 206 residues (18).
###end p 6
###begin p 7
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c32">32</xref>
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c33">33</xref>
###xml 823 831 823 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 83 88 <span type="species:ncbi:9606">human</span>
###xml 225 230 <span type="species:ncbi:9606">human</span>
###xml 581 586 <span type="species:ncbi:9606">human</span>
###xml 685 690 <span type="species:ncbi:9606">human</span>
Here, we address the question of what role this region plays in the functioning of human topo I inside a living cell. For this purpose we removed, at the N-terminal end, either 190 or 210 amino acid residues, and established human cell lines expressing bio-fluorescent chimera of these truncated enzymes. We used a bicistronic expression vector (32), conferring stable and permanent expression of the fluorescent enzymes at levels similar to that of endogenous topo I. Recently this approach has allowed us to investigate localization, mobility and DNA-interactions of full-length human topo I in substructures of the living cell nucleus (33). By this same approach, we show here that human topo I lacking amino acids 190-210 does not interact in a catalytic manner with the DNA inside a living cell, although it is active in vitro.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Constructs and cell culture
###end title 9
###begin p 10
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c28">28</xref>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c33">33</xref>
###xml 251 258 251 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">190&#8211;765</sup>
###xml 266 273 266 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 310 316 310 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Phe723</sup>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c32">32</xref>
###xml 588 589 588 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 858 860 858 860 <bold xmlns:xlink="http://www.w3.org/1999/xlink">YK</bold>
###xml 876 877 876 877 <bold xmlns:xlink="http://www.w3.org/1999/xlink">K</bold>
###xml 877 880 877 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink">190</sup>
###xml 880 881 880 881 <bold xmlns:xlink="http://www.w3.org/1999/xlink">K</bold>
###xml 881 884 881 884 <sup xmlns:xlink="http://www.w3.org/1999/xlink">191</sup>
###xml 889 891 889 891 <bold xmlns:xlink="http://www.w3.org/1999/xlink">YK</bold>
###xml 907 908 907 908 <bold xmlns:xlink="http://www.w3.org/1999/xlink">R</bold>
###xml 908 911 908 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210</sup>
###xml 911 912 911 912 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Y</bold>
###xml 912 915 912 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink">211</sup>
###xml 930 937 930 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink">190&#8211;765</sup>
###xml 952 959 952 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1327 1329 1323 1325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 1404 1406 1400 1402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c28">28</xref>
###xml 1407 1409 1403 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c33">33</xref>
###xml 191 196 <span type="species:ncbi:9606">human</span>
###xml 346 351 <span type="species:ncbi:9606">human</span>
###xml 683 693 <span type="species:ncbi:138953">poliovirus</span>
###xml 805 809 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Cell lines supporting stable expression of fusion proteins of green fluorescent protein (GFP) and variants of topo I followed published protocols (28,33). Briefly, GFP-chimera of full-length human topo I, of the N-terminally truncated fragments topo I190-765, topo I210-765 and of the active site mutant topo IPhe723 were stably expressed in the human embryonal kidney cell line 293 (German Collection of Micro organisms and Cell Cultures, Braunschweig, Germany) using the bicistronic expression vector pMC-2P (32), in which the translational initiation of the selection marker puromycin-N-acetyl transferase in the second cistron is mediated by an internal ribosome entry site from poliovirus. Since the N-terminally truncated versions of topo I lack a NLS, PCR-primers were supplemented with the NLS of SV40 (PKKKRKV), thus generating amino acid sequences YK-RWTRPPKKKRKVPP-K190K191 and YK-RWTRPPKKKRKVPP-R210Y211 for GFP-topo I190-765 and GFP-topo I210-765, respectively. (The last amino acids of GFP and the first ones of topo I are indicated in bold letters.) Cells grown in DMEM supplemented with Glutamax-I (Gibco BRL/Life Technologies, Karlsruhe, Germany) were transfected using Lipofectamine (Gibco BRL/Life Technologies, Karlsruhe, Germany). Stable transgenic cell lines were selected after 2 days with 0.35 microg ml-1 puromycin and maintained under selection. We have ascertained previously (28,33) that (i) the GFP-chimera were not heavily over-expressed, (ii) the chimeric genes were not rearranged, (iii) green fluorescence of the cells could be unambiguously assigned to constitutive expression of the intended proteins and (iv) dose response to camptothecin was equal for GFP-topo I and endogenous topo I.
###end p 10
###begin title 11
Life cell imaging
###end title 11
###begin p 12
###xml 169 170 169 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 456 457 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1012 1013 1006 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1013 1016 1007 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rel</italic>
###xml 1013 1016 1007 1010 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>rel</italic></sub>
###xml 1046 1048 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c34">34</xref>
For confocal imaging and for measurements of fluorescence recovery after photobleaching (FRAP), we used a Zeiss LSM 510 inverted confocal laser scanning microscope. A CO2-controlled on-stage heated cell chamber and a heated 63x/1.4 NA oil-immersion objective were used, thus allowing culturing of the cells under the microscope at 37degreesC. For FRAP measurements, fluorescent images of a single optical section were taken at 1.6 s time intervals before (n = 5) and after bleaching of a circular area at 20 mW nominal laser power with three iterations. Imaging scans were acquired with the laser power attenuated to 0.1-1% of the bleaching intensity. For a quantitative analysis of FRAP, fluorescence intensities of the bleached region and the entire cell nucleus were measured at each time point. Data were corrected for extra-cellular background intensity and for the overall loss in total intensity as a result of the bleach pulse itself and of the imaging scans. The relative intensity of the bleached area Irel was calculated according to (34). We ascertained that FRAP results were independent of the expression level of GFP-topo I, in as much as we failed to detect any differences in FRAP between individual cells exhibiting strong or weak GFP fluorescence within a cell population expressing the same construct.
###end p 12
###begin title 13
Protein purification
###end title 13
###begin p 14
###xml 32 39 32 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c35">35</xref>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c36">36</xref>
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 619 626 619 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1079 1086 1079 1086 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1137 1138 1125 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
Endogenous topo I and GFP-topo I210-765 from the same batch of transfected 293 cells were purified as described in (35,36) and summarized in Figure 2A. Endogenous topo I was adsorbed from nuclear extracts (330 mM NaCl) to Ni-NTA-Sepharose (Quiagen, Hilden, Germany), eluted from there with 200 mM imidazol, then adsorbed to phenyl-Sepharose (Amersham-Pharmacia-Biotech, Freiburg, Germany) in the presence of 0.9 M ammonium sulfate, and finally eluted from the latter resin with buffer lacking ammonium sulfate. The enzyme was thus purified to apparent homogeneity and had the expected size (Fig. 2B, lane 3). GFP-topo I210-765 present in the same nuclear extracts was separated from endogenous topo I, as it did not bind to Ni-NTA-Sepharose. It was recovered from the effluent of the Ni-NTA column by hydrophobic interaction chromatography (as described above) and further purified by adsorption to heparin-Sepharose (Amersham-Pharmacia-Biotech, Freiburg, Germany), followed by elution with 800 mM NaCl. In the final eluate endogenous topo I or topo II were absent and GFP-topo I210-765 constituted approximately70% of the protein (Fig. 2B, lane 2).
###end p 14
###begin title 15
Immunoblotting
###end title 15
###begin p 16
###xml 322 324 318 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 348 350 340 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 394 395 386 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 773 779 <span type="species:ncbi:9986">rabbit</span>
###xml 857 862 <span type="species:ncbi:9606">human</span>
###xml 917 922 <span type="species:ncbi:10090">mouse</span>
###xml 1048 1052 <span type="species:ncbi:9925">goat</span>
###xml 1058 1064 <span type="species:ncbi:9986">rabbit</span>
###xml 1068 1072 <span type="species:ncbi:9925">goat</span>
###xml 1078 1083 <span type="species:ncbi:10090">mouse</span>
###xml 1651 1655 <span type="species:ncbi:9913">calf</span>
We analyzed either nuclear extracts, or whole cell lysates. Whole cell lysates were prepared by adding to cells suspended in PBS an equal volume of 2-fold lysis buffer [25 mM Tris-HCl, pH 6.8, 10% SDS, 8 M urea, 20% glycerol, 0.04% bromophenol blue, 10 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride, 1 mM PMSF, 20 microg ml-1 aprotinin, 10 microg ml-1 pepstatin A]. Material equivalent to 5 x 105 cells was then applied to each slot of an SDS-gel (8% polyacrylamide). After electrophoresis, proteins were electro-blotted onto PVDF-membranes (Immobilon P, Millipore, Bedford, MD). The membranes were subsequently blocked with PBS, containing 2% BSA, 0.05% Tween 20, and then incubated for 1 h with the primary antibodies diluted with the same buffer. Topo I was stained with rabbit peptide antibodies against the last 18 C-terminal amino acid residues of the human enzyme (Genosys, Cambridge, UK). GFP was stained with mouse monoclonal antibodies (Clontech, Heidelberg, Germany). After washing, the filters were incubated for 1 h with HRP-conjugated goat anti-rabbit or goat anti-mouse antibodies diluted with PBS containing 2% BSA and 0.1% Tween 20. Following extensive washing with the same buffer, labelled protein bands were finally visualized with the ECL Plus system (Amersham Pharmacia Biotech, Freiburg, Germany). For immuno-band depletion, cells were first incubated with camptothecin (20 min) and the same concentration of drug was also added to the lysis buffer. Immuno-band depletion assays with nuclear extracts were carried out under the same conditions as plasmid-relaxation assays (see next paragraph), with the exception that 0.1 mg/ml calf thymus DNA was added to the reaction and the reaction product was applied to an SDS-protein gel instead of an agarose DNA-gel.
###end p 16
###begin title 17
Sequential salt extraction of nuclei
###end title 17
###begin p 18
###xml 60 61 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 100 101 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 212 214 208 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 238 240 230 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 264 266 252 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 289 291 273 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 317 319 297 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 670 671 650 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 753 754 727 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 858 860 824 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 883 885 845 847 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 929 931 887 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 1105 1106 1063 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
Exponentially growing cells were harvested, sedimented (600 g, 3 min), carefully resuspended (5 x 109 cells/3 ml) in lysis buffer [10% sucrose, 15 mM HEPES pH 7.5, 0.5 mM EGTA, 60 mM KCl, 15 mM NaCl, 30 microg ml-1 spermine, 7.5 microg ml-1 spermidine, 5 microg ml-1 leupeptin, 5 microg ml-1 pepstatin A, 10 microg ml-1 aprotinin, 1 mM DTT, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride, 1 mM PMSF], and incubated for 5 min on ice to allow for cell swelling. Cells were then lysed by addition of Triton-X-100 to a final concentration of 0.5%, followed by a brief incubation (2 min on ice). Nuclei were then purified by centrifugation across a 20% sucrose-cushion (1500 g, 15 min, 4degreesC), washed once with lysis buffer, and finally extracted (5 x 109 nuclei/200 microl) with 100 mM NaCl in extraction buffer [50 mM HEPES pH 7.5, 0.5 mM EDTA, 50 microg ml-1 leupeptin, 5 microg ml-1 pepstatin A, 1 mM benzamidine, 10 microg ml-1 aprotinin, 1 mM DTT, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride, 1 mM PMSF, 10% glycerol]. Nuclear remnant and extracted proteins were separated by centrifugation (2000 g, 5 min, 4degreesC). Nuclear remnant from the first extraction step was washed once in 100 mM NaCl in extraction buffer and then extracted again with 150 mM NaCl in extraction buffer, and again separated by centrifugation. This procedure was repeated with 200, 250, 300 and 400 mM NaCl. Extracted proteins from each extraction step were subjected to SDS-PAGE and GFP-directed immuno-blotting.
###end p 18
###begin title 19
RESULTS
###end title 19
###begin title 20
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
###xml 60 67 60 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 150 157 150 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">190&#8211;765</sup>
In vivo, topo I lacking the entire N-terminal domain (topo I210-765) does not respond to camptothecin, whereas topo I lacking 20 residues less (topo I190-765) does
###end title 20
###begin p 21
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f1">1</xref>
###xml 316 322 316 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Phe723</sup>
###xml 341 347 341 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Phe723</sup>
###xml 359 366 359 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">190&#8211;765</sup>
###xml 434 441 434 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">190&#8211;765</sup>
###xml 457 464 457 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 520 527 520 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 608 617 608 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro.</italic>
###xml 673 679 673 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Phe723</sup>
###xml 782 784 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c33">33</xref>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c25">25</xref>
###xml 998 1000 998 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c28">28</xref>
###xml 250 255 <span type="species:ncbi:9606">human</span>
To examine the physiological role of residues 190-210, we evaluated the cellular distribution of various GFP-topo I-chimera. Figure 1A shows in the middle representative fluorescent images of cells at interphase expressing GFP-chimera of full-length human topo I (row 1, GFP-topo I), of the active site mutant topo IPhe723 (row 2, GFP-topo IPhe723), of topo I190-765 lacking a major portion of the N-terminal domain (row 3, GFP-topo I190-765), and of topo I210-765 lacking the entire N-terminal domain (row 4, GFP-topo I210-765), which is considered the minimal portion of the enzyme retaining full activity in vitro. With the exception of the active site mutant GFP-topo IPhe723 (row 2), which resides preferentially in the nucleoplasm due to its prolonged binding to genomic DNA (33), all these constructs accumulated in the nucleoli. This conflicts with previous data (25) claiming the N-terminal domain to be required for nucleolar localization-an issue addressed in a recently published work (28).
###end p 21
###begin p 22
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f1">1</xref>
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f1">1</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c37">37</xref>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c33">33</xref>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c38">38</xref>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c39">39</xref>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c33">33</xref>
###xml 867 874 867 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1022 1023 1022 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f1">1</xref>
###xml 1129 1130 1129 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f1">1</xref>
###xml 1610 1612 1610 1612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c33">33</xref>
###xml 1638 1644 1638 1644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Phe723</sup>
###xml 1888 1894 1888 1894 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Phe723</sup>
###xml 2044 2051 2044 2051 <sup xmlns:xlink="http://www.w3.org/1999/xlink">190&#8211;765</sup>
###xml 2400 2407 2400 2407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
Here, we will concentrate on the effects of camptothecin on the nuclear distribution and the mobility of these constructs, which are demonstrated in Figure 1A, right and Figure 1B, respectively. For the understanding of these data one must keep in mind that camptothecin binds and stabilizes covalent catalytic DNA-intermediates of topo I (37). Therefore, it renders GFP-chimera of topo I less mobile in the cell. This can be measured by FRAP. Such experiments have revealed recently that camptothecin targets topo I preferentially in the nucleoplasm, thus shifting the enzyme's nuclear distribution equilibrium away from the nucleoli (33). Both effects [nucleolar de-localization (38,39) and nucleoplasmic immobilization (33)] require topo I to be active in the cell nucleus. Therefore, the two phenomena can be used as criteria for judging topo I cleavage activity in vivo. The effect of camptothecin on the localization of the various topo I constructs can be gauged by comparing the middle and right columns of Figure 1A, where GFP-fluorescence of the same set of cells is shown before and after exposure to the drug. Figure 1B shows corresponding FRAP curves determined in the nucleoplasm of cells treated with camptothecin (closed symbols) or not (open symbols). It is apparent that full-length GFP-topo I became depleted from the nucleoli in response to camptothecin, and that FRAP was much faster without camptothecin than with the drug present. This confirms our previous observation that camptothecin renders topo I less mobile in the nucleoplasm, and thus induces nucleolar depletion of the enzyme (33). In contrast, GFP-topo IPhe723 was not affected by camptothecin with respect to its localization, and FRAP curves of the active site mutant were virtually the same with and without the drug. This observation fits the fact that in lack of the active site tyrosine, GFP-topo IPhe723 does not form covalent DNA-intermediates to be targeted by camptothecin. The construct with a partial truncation of the N-terminal domain (GFP-topo I190-765) was affected by camptothecin in the same fashion as the full-length enzyme. It was depleted from the nucleoli and became less mobile in the nucleoplasm. Similar results were also obtained with constructs lacking even smaller portions of the N-terminal domain (not shown). In contrast, the construct lacking the entire N-terminal domain (GFP-topo I210-765) was hardly affected by camptothecin. It was not depleted from the nucleoli by camptothecin, and its mobility in the nucleoplasm was almost the same with or without the drug.
###end p 22
###begin title 23
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 20 27 20 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
In vitro, GFP-topo I210-765 has the same DNA-relaxation activity and the same sensitivity to camptothecin as full-length topo I at physiologically relevant salt concentrations
###end title 23
###begin p 24
###xml 72 79 72 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 123 130 123 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 271 278 271 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 305 313 305 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 315 322 315 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
###xml 334 341 334 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">190&#8211;765</sup>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f1">1</xref>
###xml 508 515 508 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c33">33</xref>
###xml 570 577 570 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">190&#8211;765</sup>
###xml 714 722 714 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 772 779 772 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 867 874 867 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 976 984 976 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 993 994 993 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 1043 1044 1043 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 1131 1132 1131 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 1373 1380 1373 1380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1465 1466 1453 1454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 1655 1662 1643 1650 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1868 1875 1856 1863 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1917 1918 1905 1906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 1974 1981 1962 1969 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 2067 2068 2055 2056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 2150 2157 2138 2145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 2503 2505 2491 2493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c16">16</xref>
###xml 2706 2707 2694 2695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 2738 2745 2726 2733 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 3058 3059 3046 3047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 3087 3095 3075 3083 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 3313 3320 3301 3308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 3343 3351 3331 3339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 3576 3578 3564 3566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c36">36</xref>
###xml 3597 3604 3585 3592 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 3689 3697 3677 3685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 3886 3894 3874 3882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 3896 3898 3884 3886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c18">18</xref>
###xml 3940 3947 3928 3935 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 4005 4006 3993 3994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 4034 4042 4022 4030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 4487 4494 4475 4482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 4812 4819 4800 4807 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 4843 4844 4831 4832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 4972 4979 4960 4967 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 5023 5024 5011 5012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 5060 5067 5048 5055 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 5158 5165 5146 5153 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1315 1320 <span type="species:ncbi:9606">human</span>
###xml 1340 1345 <span type="species:ncbi:4932">yeast</span>
###xml 3472 3477 <span type="species:ncbi:9606">human</span>
###xml 3497 3502 <span type="species:ncbi:4932">yeast</span>
###xml 4288 4293 <span type="species:ncbi:9606">human</span>
These findings suggested two alternative interpretations: (i) GFP-topo I210-765 is not performing cleavage; (ii) GFP-topo I210-765 is actively cleaving DNA, but resistant to camptothecin. To discriminate between these possibilities, we first determined whether GFP-topo I210-765 was actively cleaving DNA in vitro. In vivo, GFP-topo I190-765 and GFP-topo I have the same sensitivity towards camptothecin (Fig. 1B). Moreover, GFP-topo I and endogenous topo I are known to respond equally well to camptothecin in vivo (33). Thus, it is reasonable to assume that GFP-topo I190-765 behaves similar to endogenous topo I, at least with respect to camptothecin. Therefore, endogenous topo I is a suitable control for the in vitro assessment of the cleavage activity of GFP-topo I210-765. Following this strategy, we purified from the same batch of nuclear extract GFP-topo I210-765 and endogenous topo I, and compared the two enzyme varieties with respect to DNA-relaxation activity in vitro. Figure 2A outlines the purification strategy and Figures 2B and C demonstrate the outcome with respect to enzyme purity. The top panel of Figure 2B shows the result of SDS-gel electrophoresis followed by protein staining. It can be seen that endogenous topo I (lane 3) was purified to apparent homogeneity similar to recombinant human topo I produced in yeast (lane 1), whereas GFP-topoI210-765 (lane 2) was approximately60-70% pure. Immuno-blotting with topo I antibodies (Fig. 2B, middle) demonstrates that the major bands were indeed topo I, that the three preparations had a similar concentration of topo I, and that the enzymes were mostly not degraded. GFP-topo I210-765 (lane 2) appeared to be marginally larger than endogenous topo I. This feature was employed to exclude a contamination with endogenous topo I. First, we extended electrophoresis time to separate GFP-topo I210-765 and endogenous topo I more clearly (Fig. 2C, compare lanes 2 and 3). Secondly, we mixed GFP-topo I210-765 and endogenous topo I and demonstrated that we could separate the two proteins (Fig. 2C, lane 4). Thus, we would have detected a significant contamination of GFP-topo I210-765 with endogenous topo I by a double band. It should be noted that proteolysis in the linker domain would not show up in these blots, because they were probed with a serum against a C-terminal peptide of topo I. However, such fragments would reconstitute the so-called Core + C-terminus-topo I known to have a reduced sensitivity to camptothecin (16). Thus, they would not interfere with the camptothecin assays shown below, because they would be less active and not a likely cause of false positive results. Immunoblotting with GFP antibodies (Fig. 2B, bottom) shows that GFP-topoI210-765 (lane 2) was almost entirely separated from endogenous topo I (lane 3), which contained only insignificant contaminations of GFP-positive material. By immunoblotting with topo II-antibodies we have also ascertained that none of these preparations was contaminated with type II topoisomerases (not shown). Figure 2D shows a comparison of the in vitro DNA-relaxation activity of the enzymes, determined by the limiting dilution of DNA-relaxation endpoints (left) and by relaxation kinetics obtained with equivalent enzyme amounts (right). By both approaches, GFP-topo I210-765 (bottom) had the same in vitro activity as endogenous full-length topo I prepared from the same batch of nuclear extract (middle), whereas recombinant human topo I produced in yeast (top) was slightly less active, which represents an established finding (36). Thus, GFP-topo I210-765 relaxes supercoiled DNA as efficient as endogenous topo I under low salt conditions in vitro. However, it has been suggested that the N-terminal domain is important for DNA binding, and that topo I lacking the first 206 amino acids has a lower salt optimum than full-length enzyme in vitro (18), raising the possibility that GFP-topo I210-765 is inactive at physiological salt concentrations. Figure 2E shows a comparison of the in vitro DNA-relaxation activity of the enzymes in the presence of increasing concentrations of KCl (50-400 mM). Salt optima were determined at low (left), medium (middle) or high (right) enzyme concentrations. At high enzyme concentrations, recombinant human topo I (top) and endogenous full-length topo I (middle) exhibited the same relaxation activity. At low enzyme concentrations, both exhibited their optimum at 200 mM KCl. In contrast, GFP-topo I210-765 (bottom) was less active at high salt concentrations and had its optimum at 150 mM KCl. These observations are consistent with the notion that the N-terminal domain plays a role in DNA binding. To further corroborate this finding, we compared the salt stability of the binding to nuclear structures between GFP-topo I210-765 and GFP-topo I. Figure 2F shows a sequential salt extraction (100-400 mM NaCl) of nuclei from 293 cells expressing either GFP-topo I (top) or GFP-topo I210-765 (bottom). Fitting the data shown in Figure 2B, the nuclear binding of GFP-topo I210-765 was less salt stable than that of full-length GFP-topo I. The major fraction of GFP-topo I210-765 was extracted with 250-300 mM NaCl, whereas GFP-topo I remained stably bound until 300 mM NaCl. In conclusion, we find that topo I lacking the entire N-terminal domain is more salt sensitive and better extractable from the nuclear structure than the full-length enzyme. However, these alterations are not apparent at salt concentrations encountered inside a living cell under physiological conditions, and, therefore, should not play a crucial role.
###end p 24
###begin p 25
###xml 68 75 68 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 172 180 172 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 394 401 394 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 658 659 658 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 795 802 795 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 917 925 917 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1049 1050 1049 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c18">18</xref>
###xml 1213 1221 1213 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1396 1397 1396 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 1433 1441 1433 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1468 1475 1468 1475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1670 1671 1670 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 1681 1689 1681 1689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1735 1742 1735 1742 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1908 1916 1908 1916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 2050 2052 2050 2052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c18">18</xref>
###xml 2131 2132 2131 2132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c1">1</xref>
###xml 2218 2225 2218 2225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 2225 2233 2225 2233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 2316 2323 2316 2323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 2323 2330 2323 2330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 604 609 <span type="species:ncbi:9606">human</span>
###xml 629 634 <span type="species:ncbi:4932">yeast</span>
###xml 859 864 <span type="species:ncbi:9606">human</span>
###xml 1819 1824 <span type="species:ncbi:9606">human</span>
Consequently, we considered the alternative hypothesis of GFP-topo I210-765 being resistant to camptothecin, and investigated if DNA cleavage by this enzyme was stimulated in vitro by the drug. Figure 2G demonstrates nicking of a double stranded DNA-plasmid in the presence of camptothecin as a function of topo I concentration. DNA cleavage by endogenous topo I (middle section) and GFP-topo I210-765 (right section) was significantly stimulated by camptothecin, and it can be seen clearly that in this respect the two sets of enzyme had a capacity similar to each other and also similar to recombinant human topo I produced in yeast (left section). Figure 2H demonstrates nicking of plasmid-DNA by the three sets of enzymes as a function of camptothecin concentration. It shows that GFP-topo I210-765 (right), endogenous topo I (middle) and the recombinant human enzyme (left) had a similar sensitivity to the drug in vitro. Again we needed to take into account that topo I becomes more sensitive to salt, when lacking the entire N-terminus (Fig. 2E) (18). To exclude this as a possible reason for the apparent camptothecin resistance of the enzyme inside the cell, we measured camptothecin-induced DNA-nicking in vitro in the presence of increasing concentrations of KCl (50-150 mM) or KGlu (33-100 mM), the latter resembling most closely the physiological intracellular saline milieu. Figure 2I (right section) demonstrates that in vitro DNA cleavage by GFP-topo I210-765 was not affected by KCl (top) or KGlu (bottom) within a concentration range to be encountered inside a living cell under physiological conditions. In summary, we concluded from these data (Fig. 2D-I) that in vitro and at optimal salt concentrations GFP-topo I210-765 was indistinguishable from endogenous topo I or the full-length recombinant human enzyme in as much as it was neither inactive, nor resistant to camptothecin. These in vitro-observations conform to the established finding that the N-terminal domain influences the salt sensitivity of topo I to some extent (18), but otherwise is mostly dispensable for the catalytic action of the enzyme (1), and that linkage to GFP does not appear to influence enzymatic properties of topo I210-765in vitro. These observations are however in striking contrast to the behavior of GFP-topo I210-765in vivo.
###end p 25
###begin title 26
###xml 33 40 33 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 70 78 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 94 101 94 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
By a comparable assay, GFP-topo I210-765 is sensitive to camptothecin in vitro, but resistant in vivo
###end title 26
###begin p 27
###xml 89 96 89 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 96 103 96 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 110 111 110 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f1">1</xref>
###xml 124 132 124 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f2">2</xref>
###xml 407 415 407 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 496 503 496 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 503 510 503 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 515 523 515 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 638 645 638 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 724 732 724 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1126 1127 1126 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f3">3</xref>
###xml 1252 1259 1252 1259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1345 1353 1345 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1469 1470 1469 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f3">3</xref>
###xml 1489 1496 1489 1496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1807 1814 1799 1806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1835 1836 1827 1828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f1">1</xref>
###xml 1855 1862 1847 1854 <sup xmlns:xlink="http://www.w3.org/1999/xlink">190&#8211;765</sup>
###xml 1996 2004 1984 1992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 2011 2012 1999 2000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f3">3</xref>
###xml 2065 2072 2053 2060 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 2450 2459 2434 2443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro.</italic>
###xml 1429 1433 <span type="species:ncbi:9913">calf</span>
The most plausible hypothesis explaining the discrepancy of data obtained with GFP-topo I210-765in vivo (Fig. 1A and B) and in vitro (Fig. 2D-I) would be that the innermost part of the N-terminal domain (i.e. the region spanning residues 190-210) is crucially required for the activity and/or the camptothecin sensitivity of the enzyme inside the living cell, whereas it is dispensable for these properties in vitro. We corroborated this notion by comparing camptothecin sensitivity of GFP-topo I210-765in vivo and in vitro by immuno-band depletion, a biochemical assay that can be carried out in a similar manner with intact cells (i.e. in vivo) and with nuclear extracts supplemented with a surrogate of genomic DNA (i.e. in vitro). In both constellations, the enzyme will be trapped in large DNA-protein complexes upon addition of camptothecin, provided it is capable of interacting with DNA and sensitive to the drug. Thus, the active and camptothecin-sensitive fraction of the enzyme will be prevented from entering an SDS-polyacrylamide gel, and consequently will not be detectable in subsequent immuno-blotting. Figure 3 demonstrates a dose response curve obtained by treating a mixture of 293 cells expressing equal amounts of either GFP-topo I210-765 or full-length GFP-topo I with various concentrations of camptothecin, and a similar in vitro curve obtained by treating nuclear extracts of such cells substituted with calf thymus DNA. Inside the cells (Fig. 3, left), GFP-topo I210-765 (the lower band) was completely resistant to camptothecin, since it was not depleted upon exposing the cells to concentrations of the drug as high as 100 microM. In contrast, full-length GFP-topo I (the upper band) was completely lost from the blots at concentrations higher than 1 microM. Consistent with the in vivo situation in Figure 1A and B, GFP-topo I190-765 was also efficiently depleted at camptothecin concentrations >1 microM (not shown). A completely different situation was encountered in vitro (Fig. 3, right). Here, full-length GFP-topo I and GFP-topo I210-765 were both sensitive to camptothecin in a similar fashion. They both disappeared from the blot, when camptothecin was added to the assay at concentrations >1 microM. Taken together, these findings confirm that a region spanning residues 190-210 is absolutely required for topo I to be targeted by camptothecin inside the living cell, whereas it is dispensable for this property in vitro.
###end p 27
###begin title 28
DISCUSSION
###end title 28
###begin p 29
###xml 191 199 191 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 369 376 369 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 381 389 381 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 684 691 684 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 841 843 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c40">40</xref>
###xml 854 856 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c41">41</xref>
###xml 869 871 869 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c42">42</xref>
###xml 960 967 960 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1004 1005 1004 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg927f1">1</xref>
###xml 32 37 <span type="species:ncbi:9606">human</span>
We show here that a fragment of human topo I lacking the entire N-terminal domain up to position 210 is not stabilized by camptothecin in covalent DNA-complexes inside a living cell, whereas in vitro it is targeted by camptothecin in the usual manner and retains full DNA-relaxation activity at physiologically relevant salt concentrations. This difference in behavior in vivo and in vitro is not shared with a fragment lacking the N-terminal domain up to residue 190 or smaller portions of it. Thus, our findings indicate residues 190-209 of topo I to play a crucial role for the activity of the enzyme in its physiological environment. Unfortunately, topo I DNA-relaxation activity in vivo cannot be measured directly. It can only be approximated from camptothecin stabilized cleavage activity [using assays such as immuno-band depletion (40), LM-PCR (41) or tardis (42)]. Consequently, we cannot discriminate whether the apparent insensitivity of GFP-topo I210-765 to camptothecin indicated in Figure 1A and B is due to inactivity or drug resistance, and whether residues 190-209 are required for topo I to form covalent intermediates with genomic DNA, or just for camptothecin to bind and stabilize such complexes in the cell.
###end p 29
###begin p 30
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c43">43</xref>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c16">16</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c30">30</xref>
###xml 506 513 506 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 532 539 532 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 783 790 783 790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 939 941 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c28">28</xref>
The latter possibility, however, seems unlikely, since all residues and portions of topo I known to confer camptothecin resistance at the cellular level are placed around the active center (43) or in the linker domain (16) and not in the N-terminal domain. In keeping with this, the X-ray crystal structure of the topo I-DNA cleavage complex (30) did not suggest a role for the N-terminal domain in the interplay between drug, DNA and topo I. Thus, resistance seems an unlikely explanation for the lack of in vivo response of topo I210-765 to camptothecin. More likely, it seems that the enzyme has a dramatically reduced activity inside the living cell, when it lacks the N-terminal domain including residues 190-210. This notion is also supported by the observation that GFP-topo I210-765 appears to be less toxic to the cells than full-length topo I, since heterologous expression of this fragment is tolerated at 4-fold higher levels (28).
###end p 30
###begin p 31
###xml 169 176 169 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 208 216 208 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 244 252 244 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 452 457 452 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c18">18</xref>
###xml 561 568 561 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 963 966 963 966 <sup xmlns:xlink="http://www.w3.org/1999/xlink">203</sup>
###xml 975 978 975 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink">346</sup>
###xml 989 992 989 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink">205</sup>
###xml 997 1000 997 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink">206</sup>
###xml 1137 1139 1137 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c31">31</xref>
###xml 1872 1874 1864 1866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c44">44</xref>
###xml 1951 1959 1943 1951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 2239 2246 2231 2238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 3250 3258 3242 3250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 3326 3327 3318 3319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c9">9</xref>
###xml 3328 3330 3320 3322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c20">20</xref>
###xml 3331 3333 3323 3325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg927c23">23</xref>
###xml 70 75 <span type="species:ncbi:9606">human</span>
This reasoning implies that a region ranging from residues 190-210 of human topo I must somehow play a direct role in the catalytic cycle, and that this role is crucial in vivo, but not or only marginally so in vitro. It has been reported that in vitro the catalytic properties of topo I lacking the N-terminal domain up to position 206 are slightly different from those of the full-length enzyme. Most notably, DNA-relaxation is more distributive and trans-ligation to external DNA-pieces is impeded (18). In keeping with this, we observed here that GFP-topo I210-765 is better salt extractable from the nuclear structure and its activity is more salt sensitive. These features could indicate a reduced binding affinity to DNA and other nuclear proteins, which suggests that removal of the entire N-terminal domain changes conformation of the enzyme in a global manner. This is plausible in the light of recent structural data proposing a physical contact of Trp203 with His346 and of Trp205, Trp206 with the hinge region of the core domain, which determines flexibility of the enzyme clamp and allows for a control of strand rotation (31). In synopsis, these findings suggest that in the absence of the entire N-terminal domain including region 190-210, flexibility of topo I could be altered. Recent reconstitution experiments have shown that the 'cap' of topo I (amino acid residues 175-432) complements DNA cleavage by a portion of topo I comprising residues 433-765 ('Deltacap'), which lacks catalytic activity, although it contains all of the residues known to be important for catalysis and binds DNA with an affinity similar to that of the intact enzyme. These findings suggest that, when topo I binds DNA, two opposing lobes in the enzyme clamp tightly around the DNA helix to form the pre-cleavage complex, one of them being the 'cap' and the other 'Deltacap' (44). Interestingly, only part of the 'cap' (i.e. 210-432) seems to be required in vitro for catalytic activity. However, considering the complexity of the DNA-structures encountered by topo I within the mammalian genome, and considering the highly limited space provided in the cell nucleus for the enzyme's interactions with these structures, one could imagine that in vivo the flexibility of the enzyme clamp might actually become a factor that limits DNA-interactions of topo I in a more general manner. Thus, it can well be that an enzyme lacking the entire N-terminal domain is altogether precluded from engaging in catalytic DNA-interactions inside the living cell because the flexibility of the enzyme clamp is improperly controlled, whereas this does not play a role, when the same enzyme fragment deals in a test tube with comparably simple substrate molecules such as DNA-plasmids or oligonucleotides. On the other hand, residues 190-210 might contain interaction domains of nuclear proteins that position topo I in the nucleus and thus facilitate its activity in living cells. This view is clearly supported by the altered extractability of the truncated enzyme shown here, and by the striking observation that all proteins shown so far to interact with topo I bind the N-terminal domain. Moreover, some of these proteins have been shown to stimulate topo I activity in vitro and thus could be required for its functioning in the living cell (9,20-23).
###end p 31
###begin title 32
Figures and Tables
###end title 32
###begin p 33
###xml 122 123 122 123 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 248 254 248 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Phe723</sup>
###xml 301 308 301 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">190&#8211;765</sup>
###xml 319 326 319 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 492 493 488 489 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 205 210 <span type="species:ncbi:9606">human</span>
 Distribution, mobility and camptothecin sensitivity of various topo I-fragments, expressed as GFP-chimera in 293 cells. (A) Fluorescent images of cells at interphase expressing GFP-chimera of full-length human topo I, the active site mutant topo IPhe723, and the N-terminally truncated enzymes topo I190-765 and topo I210-765 are shown before (middle) and after (right) exposure to camptothecin (20 microM, 20 min). Corresponding images obtained by transmitted light are shown on the left. (B) FRAP curves determined in the nucleoplasm of cells treated with 20 microM camptothecin for 20 min (closed triangles) or not (open triangles). The lines represent all data points, some of which are highlighted by symbols. The actual bleach spots are indicated in the corresponding confocal images of GFP-fluorescence of the cells, shown at the top of the curves.
###end p 33
###begin p 34
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 89 96 89 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 159 160 159 160 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 189 190 189 190 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 312 319 312 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 593 594 593 594 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 777 784 777 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 842 849 842 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 874 875 874 875 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 1029 1036 1029 1036 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1375 1376 1375 1376 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 1522 1529 1522 1529 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 1740 1741 1740 1741 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 1763 1770 1763 1770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1847 1854 1847 1854 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 2109 2110 2109 2110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 2456 2457 2452 2453 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H</bold>
###xml 2695 2696 2687 2688 <bold xmlns:xlink="http://www.w3.org/1999/xlink">I</bold>
###xml 262 267 <span type="species:ncbi:9606">human</span>
###xml 287 292 <span type="species:ncbi:4932">yeast</span>
###xml 727 732 <span type="species:ncbi:9606">human</span>
###xml 752 757 <span type="species:ncbi:4932">yeast</span>
In vitro-assessment of DNA-relaxation and camptothecin-induced DNA-cleavage by GFP-topo I210-765 and endogenous topo I purified from the same batch of cells. (A) Strategy of purification. (B) Characterization of purified enzymes. Lane 1: recombinant full-length human topo I produced in yeast. Lane 2: GFP-topo I210-765. Lane 3: Endogenous topo I. (Top) SDS-gel electrophoresis (7.5% polyacrylamide gels) followed by protein staining with silver nitrate. (Middle) Western-blotting and immuno-staining with topo I antibodies. (Bottom) Western-blotting and immuno-staining with GFP antibodies. (C) Characterization of purified enzymes. Western-blotting and immuno-staining with topo I antibodies. Lane 1: recombinant full-length human topo I produced in yeast. Lane 2: GFP-topo I210-765. Lane 3: Endogenous topo I. Lane 4: Mixture of GFP-topo I210-765 and endogenous topo I. (D) DNA-relaxation: supercoiled pUC18 plasmid-DNA (300 ng) was either reacted with increasing amounts of recombinant topo I, endogenous topo I or GFP-topo I210-765 (the wedge indicates serial 1: two dilutions of the enzymes starting with 3 ng for a fixed time of 20 min (left), or it was reacted with a fixed amount (1 ng) of the enzymes for various time periods (right). DNA-electrophoresis was in the absence of ethidium bromide in order to separate supercoiled (SC) and relaxed (RL) plasmid forms. (E) Salt optimum for DNA-relaxation. Similar reactions as in (D) were done with fixed amounts of recombinant topo I, endogenous topo I or GFP-topo I210-765 and increasing KCl concentrations (wedges indicate 50, 75, 100, 125, 150, 200, 300, 400 mM KCl) for a fixed time of 20 min. Bars indicate increasing amounts (0.25, 0.5, 1 ng) of enzyme added to the reactions. (F) Salt extractability in vivo. Nuclei from 293 cells expressing full-length GFP-topo I (top) or GFP-topo I210-765 (bottom) were sequentially extracted with increasing amounts of NaCl, and extracted proteins were subjected to GFP-directed immuno-blotting. The wedge indicates increasing amounts of salt (100, 150, 200, 250, 300, 400 mM NaCl) in the extraction buffer. (G) DNA-cleavage: similar reactions as in (D) were done in the absence (left) or presence (right) of 10 microM camptothecin (CpT). Wedges indicate increasing amounts (5, 20, 40, 80 ng) of enzyme added to the reactions. DNA-electrophoresis was in the presence of ethidium bromide in order to separate closed (SC, RL) and nicked (OC) plasmid forms. (H) Camptothecin sensitivity: similar reactions as in (G) were done with a fixed amount (40 ng) of purified topo I in the presence of increasing concentrations of camptothecin (0.1, 0.5, 1, 2, 5, 10 and 20 microM are indicated by wedges). (I) Salt stability: similar reactions as in (G) were done in the presence of increasing amounts of KCl (50, 100, 150 mM) or KGlu (33, 66, 100 mM). In the latter case, KGlu also served as a buffer substance. After adjustment with KOH to pH 7.9 the ratio of K to Glu was 2:1. Thus, KCl (top) and KGlu (bottom) are compared under the wedges at comparable ionic strength.
###end p 34
###begin p 35
###xml 57 64 57 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 161 168 161 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">210&#8211;765</sup>
###xml 433 435 425 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 439 443 <span type="species:ncbi:9913">calf</span>
###xml 658 662 <span type="species:ncbi:9913">calf</span>
 Camptothecin-induced immuno-band depletion of GFP-topo I210-765 and full-length GFP-topo I in intact cells and nuclear extracts. 293 cells expressing GFP-topo I210-765 were mixed in a 1:4 ratio with 293 cells expressing full-length GFP-topo I. Living cells (left), or nuclear extracts thereof (right) were then treated for 20 min with various concentrations of camptothecin. Nuclear extracts were supplemented with 0.1 microg microl-1 of calf thymus DNA prior to the incubation. Incubations were stopped with lysis buffer and samples were subjected to GFP-directed immuno-blotting. The two outmost lanes on the left of the right panel show controls without calf thymus DNA +/- camptothecin at the maximal concentration.
###end p 35
###begin title 36
ACKNOWLEDGEMENTS
###end title 36
###begin p 37
###xml 226 232 226 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Phe723</sup>
We are grateful to Jorg Hacker and Hilde Merkert of the Research Center for Infectious Diseases, University of Wurzburg, Germany, for generously providing access to their confocal laser-scanning microscope. The clone of topo IPhe723 was a generous gift of James J. Champoux, Department of Microbiology, University of Washington, Seattle, USA. Our work has been supported by the Deutsche Forschungs gemeinschaft (Bo 910/3-1, Bo 910/4-1, GRK 639 and HA 1434/13-1).
###end p 37
###begin title 38
REFERENCES
###end title 38

